These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24881063)

  • 1. Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD.
    Verhamme KM; Sturkenboom MC; Brusselle GG
    Eur Respir J; 2014 Jun; 43(6):1818-9. PubMed ID: 24881063
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD.
    Meyer CN
    Eur Respir J; 2014 Jun; 43(6):1816-8. PubMed ID: 24881062
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
    Verhamme KM; Afonso A; Romio S; Stricker BC; Brusselle GG; Sturkenboom MC
    Eur Respir J; 2013 Sep; 42(3):606-15. PubMed ID: 23520322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
    Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
    Ichinose M; Fujimoto T; Fukuchi Y
    Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiotropium Respimat inhaler and the risk of death in COPD.
    Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
    N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    Caillaud D; Le Merre C; Martinat Y; Aguilaniu B; Pavia D
    Int J Chron Obstruct Pulmon Dis; 2007; 2(4):559-65. PubMed ID: 18268929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
    Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
    Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.
    Wise RA; Anzueto A; Calverley P; Dahl R; Dusser D; Pledger G; Koenen-Bergmann M; Joseph E; Cotton D; Disse B
    Respir Res; 2013 Apr; 14(1):40. PubMed ID: 23547660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
    Dahl R; Kaplan A
    BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.
    Trotta F; Da Cas R; Rajevic M; Rossi M; Traversa G
    BMJ Open; 2015 May; 5(5):e006619. PubMed ID: 26009573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
    Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
    Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
    Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiotropium and the risk of death in COPD.
    Jenkins CR
    N Engl J Med; 2014 Jan; 370(5):482-3. PubMed ID: 24482820
    [No Abstract]   [Full Text] [Related]  

  • 16. Tiotropium and the risk of death in COPD.
    Verhamme KM; van Blijderveen N; Sturkenboom MC
    N Engl J Med; 2014 Jan; 370(5):481-2. PubMed ID: 24476443
    [No Abstract]   [Full Text] [Related]  

  • 17. Tiotropium and the risk of death in COPD.
    Loke YK; Singh S; Furberg CD
    N Engl J Med; 2014 Jan; 370(5):480-1. PubMed ID: 24476442
    [No Abstract]   [Full Text] [Related]  

  • 18. Tiotropium and the risk of death in COPD.
    Wise RA
    N Engl J Med; 2014 Jan; 370(5):482. PubMed ID: 24476441
    [No Abstract]   [Full Text] [Related]  

  • 19. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
    Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiotropium effective in treatment of COPD.
    Kripke C
    Am Fam Physician; 2005 Dec; 72(11):2219-20. PubMed ID: 16345146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.